ALUNBRIG® (brigatinib): Real-World Treatment Experience
Dr Spyridon Gennatas presents two real-world case studies following patients with ALK+ aNSCLC through treatment with ALUNBRIG. Watch the full expert discussion or scroll down to explore each case study separately.
Case study 1
The first case features an 80 year old female patient with a brain metastasis at presentation and how treatment was managed in this elderly patient.
Case study 2
The second case features a 48 year old patient, a parent and professional chef, who achieved an ongoing durable response with more than five years of disease control on treatment, illustrating the potential for long-term benefit in the 1L setting.
ALK+, anaplastic lymphoma kinase positive; aNSCLC, advanced non-small cell lung cancer.
To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.
